These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 26211708)

  • 1. Bivalirudin vs Heparin in Patients Who Undergo Transcatheter Aortic Valve Implantation.
    Lange P; Greif M; Bongiovanni D; Thaumann A; Näbauer M; Bischoff B; Helbig S; Becker C; Schmitz C; D'Anastasi M; Mehilli J; Boekstegers P; Massberg S; Kupatt C
    Can J Cardiol; 2015 Aug; 31(8):998-1003. PubMed ID: 26211708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex-based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO-3 randomized trial.
    Asgar A; Chandrasekhar J; Mikhail G; Webb J; Lefèvre T; Tamburino C; Hildick-Smith D; Hambrecht R; Van Belle E; Widder J; Dumonteil N; Hink U; Jeger R; Linke A; Deliargyris E; Gao P; Mehran R; Hengstenberg C; Anthopoulos P; Dangas G;
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):144-153. PubMed ID: 27152677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.
    Linke A; Chandrasekhar J; Sartori S; Lefevre T; van Belle E; Schaefer U; Tchetche D; Sardella G; Webb J; Colombo A; Windecker S; Vogel B; Farhan S; Sorrentino S; Sharma M; Snyder C; Asgar A; Dumonteil N; Tamburino C; Hink U; Violini R; Stella P; Bernstein D; Deliargyris E; Hengstenberg C; Baber U; Mehran R; Anthopoulos P; Dangas G;
    Catheter Cardiovasc Interv; 2017 Nov; 90(6):1016-1026. PubMed ID: 28498562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial.
    Dangas GD; Lefèvre T; Kupatt C; Tchetche D; Schäfer U; Dumonteil N; Webb JG; Colombo A; Windecker S; Ten Berg JM; Hildick-Smith D; Mehran R; Boekstegers P; Linke A; Tron C; Van Belle E; Asgar AW; Fach A; Jeger R; Sardella G; Hink HU; Husser O; Grube E; Deliargyris EN; Lechthaler I; Bernstein D; Wijngaard P; Anthopoulos P; Hengstenberg C;
    J Am Coll Cardiol; 2015 Dec; 66(25):2860-2868. PubMed ID: 26477635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO-3 randomized trial.
    Zilberszac R; Chandiramani R; Hengstenberg C; Sartori S; Cao D; Chandrasekhar J; Schafer U; Tchetche D; Violini R; Jeger R; Van Belle E; Boekstegers P; Hambrecht R; Tron C; Dumenteil N; Linke A; Ten Berg JM; Deliargyris EN; Anthopoulos P; Mehran R; Dangas G
    Catheter Cardiovasc Interv; 2020 Sep; 96(3):E377-E386. PubMed ID: 31808295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty.
    Kini A; Yu J; Cohen MG; Mehran R; Baber U; Sartori S; Vlachojannis GJ; Kovacic JC; Pyo R; O'Neill B; Singh V; Jacobs E; Poludasu S; Moreno P; Kim MC; Krishnan P; Sharma SK; Dangas GD
    EuroIntervention; 2014 Jul; 10(3):312-9. PubMed ID: 24273237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice.
    Showkathali R; Davies JR; Parker M; Taggu W; Tang KH; Clesham GJ; Gamma RA; Sayer JW; Aggarwal RK; Kelly PA
    Cardiovasc Revasc Med; 2013; 14(5):289-93. PubMed ID: 23972537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    White HD; Chew DP; Hoekstra JW; Miller CD; Pollack CV; Feit F; Lincoff AM; Bertrand M; Pocock S; Ware J; Ohman EM; Mehran R; Stone GW
    J Am Coll Cardiol; 2008 May; 51(18):1734-41. PubMed ID: 18452778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in percutaneous peripheral intervention: a single-center experience.
    Sheikh IR; Ahmed SH; Mori N; Gupta A; Mewissen M; Allaqaband S; Bajwa T
    JACC Cardiovasc Interv; 2009 Sep; 2(9):871-6. PubMed ID: 19778776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a meta-regression analysis of randomized trials.
    Tarantini G; Brener SJ; Barioli A; Gratta A; Parodi G; Rossini R; Navarese EP; Niccoli G; Frigo AC; Musumeci G; Iliceto S; Stone GW
    Am Heart J; 2014 Mar; 167(3):401-412.e6. PubMed ID: 24576526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
    Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
    Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and in-hospital outcomes of bivalirudin use in dialysis patients undergoing percutaneous coronary intervention.
    Delhaye C; Maluenda G; Wakabayashi K; Ben-Dor I; Collins SD; Syed AI; Gonzalez MA; Gaglia MA; Torguson R; Xue Z; Suddath WO; Satler LF; Kent KM; Lindsay J; Pichard AD; Waksman R
    Am J Cardiol; 2010 Feb; 105(3):297-301. PubMed ID: 20102938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
    Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM
    Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality.
    Ndrepepa G; Schulz S; Keta D; Mehilli J; Birkmeier A; Massberg S; Laugwitz KL; Neumann FJ; Seyfarth M; Berger PB; Schömig A; Kastrati A
    Am J Cardiol; 2010 Jan; 105(2):163-7. PubMed ID: 20102912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of bivalirudin versus heparin after transradial and transfemoral percutaneous coronary intervention.
    MacHaalany J; Abdelaal E; Bataille Y; Plourde G; Duranleau-Gagnon P; Larose É; Déry JP; Barbeau G; Rinfret S; Rodés-Cabau J; De Larochellière R; Roy L; Costerousse O; Bertrand OF
    Am J Cardiol; 2012 Dec; 110(12):1742-8. PubMed ID: 22980964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of patient outcomes with bivalirudin versus unfractionated heparin in percutaneous coronary intervention.
    Watson K; Seybert AL; Saul MI; Lee JS; Kane-Gill SL
    Pharmacotherapy; 2007 May; 27(5):647-56. PubMed ID: 17461699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of heparin and bivalirudin in patients undergoing percutaneous coronary intervention without use of glycoprotein IIb/IIIa inhibitors.
    Abtahian F; Waldo S; Jang IK
    Catheter Cardiovasc Interv; 2015 Sep; 86(3):390-6. PubMed ID: 25753749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bivalirudin versus heparin in patients undergoing percutaneous transcatheter aortic valve interventions: A systematic review and meta-analysis.
    Villablanca PA; Al-Bawardy R; Mohananey D; Maraboto C; Weinreich M; Gupta T; Briceno DF; Ramakrishna H
    J Interv Cardiol; 2017 Dec; 30(6):586-594. PubMed ID: 28833456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bivalirudin in PCI: an overview of the REPLACE-2 trial.
    Maroo A; Lincoff AM
    Semin Thromb Hemost; 2004 Jun; 30(3):329-36. PubMed ID: 15282655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
    Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN
    J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.